Impact of early detection and steroid treatment on fetal ventricular heart rate and pacemaker implantation in anti-Ro/SSA positive congenital heart block

被引:0
|
作者
Sonesson, Sven-Erik [1 ,2 ]
Ambrosi, Aurelie [2 ]
Nordenstam, Felicia [1 ,3 ]
Eliasson, Hakan [1 ,3 ]
Wahren-Herlenius, Marie [2 ,4 ]
机构
[1] Karolinska Inst, Dept Womens & Childrens Hlth, Stockholm, Sweden
[2] Karolinska Inst, Dept Med, Div Rheumatol, Stockholm, Sweden
[3] Karolinska Univ Hosp, Dept Pediat Cardiol, Stockholm, Sweden
[4] Univ Bergen, Dept Clin Sci, Broegelmann Res Lab, Bergen, Norway
基金
瑞典研究理事会;
关键词
anti-Ro/SSA; congenital heart block; fluorinated steroid; heart rate; pacemaker; treatment; PR INTERVAL; FETUSES; RISK; AUTOANTIBODIES; SURVEILLANCE; REGISTRY;
D O I
10.1111/aogs.14988
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Introduction We investigated the effects of timing of detection and transplacental fluorinated steroid treatment on ventricular heart rate (HR) and age at pacemaker implantation in fetal third-degree atrioventricular block (AVB). Material and Methods Twenty-five of 31 fetuses diagnosed with Ro/SSA autoantibody-positive AVB II-III at our tertiary fetal cardiology center (2000-2020) and AVB III as final feto-neonatal outcome were reviewed. Results AVB was detected approximately 5 weeks earlier in pregnancy if followed in a surveillance program compared to cases referred from primary care for bradycardia (20.6 [2.3] [mean (SD)] vs. 25.4 [3.2] weeks, p = 0.001). AVB detected before 24 weeks had higher HR than those detected later in gestation (63.3 [6.9] vs. 57.2 [6.9] bpm, p = 0.042), with a larger proportion having HR >60 bpm (80% vs. 33%, p = 0.041). The 17/25 cases that received treatment with fluorinated steroid were diagnosed earlier in gestation, with higher HR at diagnosis (61.7 [7.1] vs. 54.7 [6.3] bpm, p = 0.026), 1-2 weeks after diagnosis/treatment start, and before birth (65.4 [12.4] vs. 54.9 [5.7] bpm, p = 0.030) than untreated cases. Overall, 11 cases were commenced on betamimetics: three at diagnosis and eight at or after the examination made 1-2 weeks after diagnosis/treatment start, without any HR improvement. Two of 24 surviving babies were born preterm, and 4/24 received a neonatal pacemaker. Age at pacemaker implantation correlated significantly with HR before birth (Spearman R 0.57, p = 0.004), and fetuses with HR >60 bpm had a higher rate of pacemaker-free survival at three (90% vs. 40%, p = 0.018) and 12 months of age (80% vs. 13%, p = 0.002). The same trend was observed in pacemaker-free survival at 3 months of age in fluorinated steroid-treated compared to untreated cases (71% vs. 38%, ns). Conclusions Our data confirm that AVB III detected earlier in gestation have a higher HR, and suggest that this higher HR can be successfully maintained to the end of gestation in cases treated with fluorinated steroids. Fetuses with HR >60 bpm before birth had a lower rate of pacemaker implantation at 3 and 12 months of age.
引用
收藏
页码:2433 / 2441
页数:9
相关论文
共 45 条
  • [21] Remission of congenital complete heart block without anti-Ro/La antibodies: A case report
    Mitra, Souvik
    Saha, Anindya Kumar
    Sardar, Syamal Kumar
    Singh, Arun Kumarendu
    ANNALS OF PEDIATRIC CARDIOLOGY, 2013, 6 (02) : 182 - 184
  • [22] MATERNAL AUTOANTIBODIES AND CONGENITAL HEART-BLOCK - NO EVIDENCE FOR THE EXISTENCE OF A UNIQUE HEART BLOCK-ASSOCIATED ANTI-RO/SS-A AUTOANTIBODY PROFILE
    MEILOF, JF
    FROHNMULDER, IME
    STEWART, PA
    SZATMARI, A
    HESS, J
    VELDHOVEN, CHA
    SMEENK, RJT
    SWAAK, AJG
    LUPUS, 1993, 2 (04) : 239 - 246
  • [23] Plasma exchange effectively removes 52-and 60-kDa anti-Ro/SSA and anti-La/SSB antibodies in pregnant women with congenital heart block
    Tonello, Marta
    Ruffatti, Amelia
    Marson, Piero
    Tison, Tiziana
    Marozio, Luca
    Hoxha, Ariela
    De Silvestro, Giustina
    Punzi, Leonardo
    TRANSFUSION, 2015, 55 (07) : 1782 - 1786
  • [24] Transient heart block in a neonate associated with previously undiagnosed maternal anti-Ro/SSA and anti-La/SSB antibodies
    Escamilla, S. A.
    Pettersen, M. D.
    PEDIATRIC CARDIOLOGY, 2007, 28 (03) : 221 - 223
  • [25] Anti-SSA/Ro antibodies and the heart: more than complete congenital heart block? A review of electrocardiographic and myocardial abnormalities and of treatment options
    Nathalie Costedoat-Chalumeau
    Zahir Amoura
    Elisabeth Villain
    Laurence Cohen
    Jean-Charles Piette
    Arthritis Res Ther, 7
  • [26] Anti-SSA/Ro and anti-SSB/La antibody-mediated congenital heart block
    Costedoat-Chalumeau, N
    Georgin-Lavialle, S
    Amoura, Z
    Piette, JC
    LUPUS, 2005, 14 (09) : 660 - 664
  • [27] Longitudinal Analysis of Fetal Ventricular Rate for Risk Stratification in Immune Congenital Heart Block
    Shokrzadeh, Ayla
    Maltret, Alice
    Morel, Nathalie
    Costedoat-Chalumeau, Nathalie
    Driessen, Marine
    Raisky, Olivier
    Ville, Yves
    Bonnet, Damien
    Stirnemann, Julien
    FETAL DIAGNOSIS AND THERAPY, 2021, 48 (01) : 1 - 8
  • [28] Congenital Heart Block in Subsequent Pregnancies of SSA/Ro-Positive Mothers Cutting Recurrence in Half
    Strasburger, Janette F.
    Wacker-Gussmann, Annette
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 76 (03) : 303 - 305
  • [29] Recurrent Congenital Heart Block Due to Maternal Anti-Ro Antibodies: Successful Prevention of Poor Pregnancy Outcome with Hydroxychloroquine and Added Dexamethasone
    Cimpoca-Raptis, Brindusa
    Ciobanu, Anca Marina
    Gica, Nicolae
    Scutelnicu, Ana Maria
    Bouariu, Alexandra
    Popescu, Mihaela
    Panaitescu, Anca Maria
    REPRODUCTIVE MEDICINE, 2022, 3 (01): : 36 - 41
  • [30] Atrial and ventricular fetal heart rate patterns in isolated congenital complete heart block detected by magnetocardiography
    Wakai, RT
    Leuthold, AC
    Martin, CB
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1998, 179 (01) : 258 - 260